We study tumor heterogeneity using cutting-edge mass spectrometry-based proteomics of cancer clinical samples, and investigate the relation between the cancer cells and the immune system within the tumor microenvironment. We develop novel single cell proteomic approaches, and combine them with tumor analyses and bioinformatics to characterize the cellular interactions within the tumor microenvironment, and how these interactions associate with response to immunotherapy.